Imatinib Zentiva

Imatinib, the active ingredient in Imatinib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and other BCR‑ABL‑positive cancers in adult patients.

GNH USA supplies Imatinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib targets BCR‑ABL driven malignancies and is indicated for several hematologic and solid tumours.

- Chronic myeloid leukemia (CML): achieves durable hematologic and cytogenetic responses. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides remission induction and maintenance. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth in patients with KIT‑positive disease.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea - Edema (periorbital or peripheral) - Muscle cramps or weakness - Fatigue - Diarrhea - Rash or pruritus

Serious or Rare Side Effects: - Hepatotoxicity (elevated transaminases, hepatitis) - Severe neutropenia or thrombocytopenia - Cardiac failure or left ventricular dysfunction - Pulmonary arterial hypertension - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Tumor lysis syndrome

Before initiating therapy, clinicians should evaluate baseline organ function and counsel patients on potential risks.

- Monitor blood counts: perform complete blood count regularly to detect cytopenias. - Assess liver function: check transaminases and bilirubin before and during treatment. - Evaluate cardiac status: baseline echocardiogram for patients with cardiac risk factors. - Avoid in severe hepatic impairment: dose adjustment may be required. - Counsel on pregnancy risk: discuss contraception and potential fetal effects. - Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib is metabolized primarily by CYP3A4, making it susceptible to drug‑drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering plasma levels. - Concomitant use with warfarin: may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., midazolam, cyclosporine): monitor plasma concentrations. - QT‑prolonging agents (e.g., quinidine, sotalol): observe ECG for QT interval changes. - Vaccines (live attenuated): consider timing to avoid reduced immune response.